Immunosign® Immune gene expression signatures

Tumor sensitivity to immune effectors

Investigate immune response within the tumor microenvironment

Immunosign® consists in two different immune gene expression signatures: Immunosign® 15 and Immunosign® 21.

The quantification of immune gene expressions enables the measurement of the naturally occurring immune activity of the tumor and has been designed to assess particularly the adaptive immunity and the immune suppression in the tumor microenvironment. Within clinical trials, Immunosign® 15 and Immunosign® 21 can provide prognostic and predictive information for cancer immunotherapy development and guide for combination therapy strategy.


Immunosign® genes have been selected by Dr. Jérôme Galon.

Proof-of-concept for prognostic and predictive values of Immunosign® 15/21 have been obtained on retrospective cohorts of colorectal cancer patients and on 9 other cancer types(Galon et al. Immunity 2013, and personal communication, Spicer J.F. et al., 2017, Marabelle A. et al., 2017).

Immunosign® is performed on Nanostring nCounter®. A dedicated bioinformatics pipeline allows to report a comprehensive analysis of data obtained with Immunosign®.

Scientific data

Posters presented by our partners at ASCO 2017 and SITC 2017:

Characterization of anti‑CD19 chimeric antigen receptor (CAR) T cell‑mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA‑1) with axica btagene ciloleucel (axi‑cel, KTE‑C19) (J.Galon et al)

  • Evaluation of Key Immune Pathways Within the Tumor Microenvironment
  • Characterizations of top Immunosign Genes Upregulated in Tumor Tissue Early Post–axi‑cel
  • Characterization of an immune gene signature in the tumor microenvironment early after
    Anti CD19 CAR T cell treatment
  • Co‑upregulation of immune checkpoints within the tumor microenvironment resulted from CAR T Cell treatment
  • Interplay between multiple complementary immune programs deployed by CAR T cells and the innate immunity (IL‑15) within the tumor environment to induce tumor responses

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study (J.Galon, F.Hermitte et al)

See ASCO 2017 poster on Lytix Biopharma website

See SITC 2017 poster on Lytix Biopharma website

  • Elevation of tumor infiltrating lymphocytes in injected lesions was observed in 14 of 19 (75%) evaluable patients.
  • The HalioDx Immune Gene Expression Signature Immunosign® 21 analysis of LTX-315 treated tumors shows:
    • Clear effect on key genes (effector T cell, Th1 orientation, chemokines, and cytokines) involved in the immune-mediated tumor regression.
    • LTX-315 demonstrates the ability to convert cold tumors hot in cancer patients.



Interested in Immunosign® ? Contact us



Our IO Scoring Services

HalioDx newsletter subscription

Join our newsletter and be the first to get notified on new updates.

× Hide this popup.